Testopel vs. Generic Testosterone Pellets.

  • STATUS
    Recruiting
  • End date
    Mar 3, 2022
  • participants needed
    120
  • sponsor
    University of Miami
Updated on 21 March 2021
androgens
testosterone
testosterone level
klinefelter syndrome
secondary hypogonadism

Summary

The purpose of this study is to evaluate changes in vascular parameters in subjects receiving Testopel 75mg (one time) versus subjects receiving Compounded Testosterone pellets 100mg (one time) versus subjects receiving Compounded Testosterone pellets 200mg (one time) to participant with clinical hypogonadism.

Description

Hypogonadism, or low testosterone (Low T), is the deficiency in producing testosterone by the testes. Testosterone pellets is a long-acting formulation of TRT that is delivered subcutaneously to men diagnosed with low T. Advantages to subcutaneous testosterone pellets include ease of delivery and decreased risk of the medication being transfer upon skin contact to woman or children. Long acting testosterone replacement Implantation of six to 10 testosterone pellets (450 to 750 mg) increased total testosterone into the therapeutic range at 1 month post-implantation and sustained therapeutic levels (>300) for 4-6 months.

Participants will be randomly assigned to 1 of 3 study groups. In one of the groups the treatment will include implantation of Testopel 750mg (10 pellets with 75mg pellet) one time, in the second group, treatment will include compounded subcutaneous testosterone 800mg (8 pellets with 100mg pellet) one time and in the third group, treatment will include compounded subcutaneous testosterone 800mg (4 pellets with 200mg pellet) one time.

The treatment takes approximately 30 minutes and will include: Clean and numb the insertion site with lidocaine at 1%, followed by small incision in the skin, implantation of pellets into subdermal fat layer and sealing the incision with Steri-strip. This is the current standard of care of Testopel insertion and same procedure will be followed with both compounded and commercial pellets.

Details
Condition Hypogonadism
Treatment Testopel, Testopel, Testosterone Pellet, 100Mg, Testosterone Pellet, 200 Mg
Clinical Study IdentifierNCT04523480
SponsorUniversity of Miami
Last Modified on21 March 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 75 yrs?
Are you male?
Do you have Hypogonadism?
Do you have any of these conditions: Do you have Hypogonadism??
Do you have any of these conditions: Do you have Hypogonadism??
Do you have any of these conditions: Do you have Hypogonadism??
Voluntarily sign and date the study consent form(s), which have been approved by an Institutional Review Board (IRB). Written consent must be obtained prior to the initiation of any study procedures
Male between 18 and 75 years of age
Documented diagnosis of primary hypogonadism (congenital or acquired) or hypogonadotropic hypogonadism (congenital or acquired)
Serum total testosterone < 300 ng/dL on 2 measurements
Nave to androgen replacement or has discontinued current treatment and completed a washout of 4 weeks following androgen treatment
Judged to be in good general health as determined by the principal investigator based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead electrocardiogram (ECG)

Exclusion Criteria

History of significant sensitivity or allergy to androgens, or product excipients
Clinically significant findings in the pre-study examinations including abnormal breast examination requiring follow-up, abnormal ECG
Abnormal prostate digital rectal examination (DRE) with palpable nodule(s) or International Prostate Symptom Score (I-PSS) score > 19 points
Body mass index (BMI) 40 kg/m2
Clinically significant abnormal laboratory value, in the opinion of the investigator, in serum chemistry, hematology, or urinalysis including but not limited to
Baseline hemoglobin > 16 g/dL
Hematocrit < 35% or > 50%
PSA > 4 ng/mL
History of seizures or convulsions, including febrile, alcohol or drug withdrawal seizures
History of any clinically significant illness, infection, or surgical procedure within 4 weeks prior to study drug administration
History of stroke or myocardial infarction within the past 5 years
History of, or current or suspected, prostate or breast cancer
History of diagnosed, severe, untreated, obstructive sleep apnea
History of abuse of alcohol or any drug substance in the opinion of the investigator within the previous 2 years
Donation or loss of 550 mL or more blood volume (including plasmapheresis) or receipt of a transfusion of any blood product within 12 weeks prior to the start of treatment
Inadequate venous access for collection of serial blood samples required for pharmacokinetic profiles
Receipt of any investigational product within 4 weeks or within 5 half-lives prior to the start of treatment
Inability to understand and provide written informed consent for the study
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note